Google Ads Policy for Peptide Brands: The Complete 2026 Guide

Google Ads policy for peptide brands is not a single document you can read and tick off. It’s an intersection of several overlapping Google policies — healthcare and medicines, unapproved pharmaceuticals, dangerous products and services, and restricted drug terms — each of which applies differently depending on how your products are positioned.

This guide explains what the policies actually say, how they apply to peptide advertising, what triggers disapprovals, and how to stay compliant in 2026.

The Four Policies That Govern Peptide Advertising

1. Healthcare and Medicines

Google’s primary healthcare policy restricts advertising for products that could be considered drugs, medicines, or health supplements without appropriate certification or approval. Peptides that are positioned as having therapeutic effects on the body fall into this category.

2. Unapproved Pharmaceuticals and Supplements

This policy targets products that make health claims without regulatory approval. Peptides marketed with therapeutic outcomes (healing, treating, curing specific conditions) are caught by this policy regardless of how they’re formally classified.

3. Dangerous Products and Services

Compounds that could be considered dangerous when used outside a research context. BPC-157 and similar peptides can trigger this policy if positioned incorrectly.

4. Restricted Drug Terms Certification (2025)

Google introduced certification requirements for advertisers using personalised targeting involving pharmaceutical terms in the US, Canada, and New Zealand. Non-certified advertisers using these targeting parameters may see campaigns limited.

What Consistently Triggers Disapprovals

• Specific medical conditions in copy or on landing pages
• Therapeutic outcome claims (“heals,” “treats,” “cures,” “clinically proven”)
• Pharmaceutical framing (“dosage,” “prescription,” “injection protocol”)
• Before/after claims with specific health metrics
• Landing pages with content that contradicts compliant ad copy

What Generally Passes Review

• Research-use framing (“research-grade,” “laboratory use only,” “for research purposes”)
• Quality and credibility signals (GMP, third-party tested, COA available)
• Audience mirroring without medical claims (“for biohackers,” “used by serious athletes”)
• Brand advertising without product-specific claims

The 2025–26 Policy Changes You Need to Know

Google made several meaningful changes to healthcare advertising policy in 2025. The most impactful: expanded automated review coverage flagging copy that previously passed, and the Restricted Drug Term Certification requirement for personalised targeting. Accounts running campaigns that worked fine in 2024 saw disruptions without warning.

See how we applied this in practice for a peptide recovery brand that reached 3.8x ROAS from a cold start.

How to Stay Compliant in 2026

1. Review all active copy against current policy quarterly
2. Check landing pages for compliance every time you update product descriptions
3. Monitor disapproval rates weekly
4. Subscribe to Google Ads policy update notifications
5. Document every appeal and the reasoning behind it

Want a Policy Audit of Your Peptide Brand’s Google Ads?

Book a free 30-minute policy audit →

Related Reading

• How to Advertise Peptides on Google Without Getting Banned
• How to Set Up Google Ads for a BPC-157 Brand: Step-by-Step
• How to Run Ads for a Peptide Supplement Brand Without Getting Banned
• Case Study: 3.8x ROAS for a Recovery Peptide Brand from Cold Start

Working with a compliant paid media agency that understands the peptide space makes the difference between sustainable growth and a banned account. Get a free strategy session with Oney Studio.